Brian Mueller - Feb 28, 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Financial Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Feb 28, 2023
Transactions value $
$0
Form type
4
Date filed
3/2/2023, 03:10 PM
Previous filing
Jan 17, 2023
Next filing
Mar 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $0 +12.7K +45.63% $0.00 40.4K Feb 28, 2023 Direct F1, F2, F3
transaction BMRN Common Stock Award $0 +11K +27.17% $0.00 51.4K Feb 28, 2023 Direct F1, F3, F4
transaction BMRN Common Stock Award $0 +1.25K +2.43% $0.00 52.6K Feb 28, 2023 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
F2 Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F3 Although earned, the RSUs only vest according to the following schedule: approximately 20% vests on March 16, 2023 and approximately 80% vests on June 29, 2023, subject to the reporting person's continued service through such dates, subject to earlier vesting upon certain events.
F4 Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F5 Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.